About Immusoft
Immusoft is a Healthcare company based in Seattle (United States) founded in 2009 by Matthew Scholz. It operates as a b cells are programmed as biofactories for therapeutic protein delivery. Immusoft has raised $44.13 million across 15 funding rounds from investors including ARE, State of California and NIH. Immusoft has completed 1 acquisition, including Discovery Genomics. Immusoft offers products and services including Immune System Programming (ISP™) and B Cell Biofactory Technology. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders. Its legal entity is IMMUSOFT CORPORATION. Its competitors include Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Immusoft was founded in 2009 in Seattle, United States, within the biotechnology sector focused on cell therapies. Patient B cells are collected, engineered to generate personalized proteins, expanded in number, and reinfused to act as ongoing production sites. This method supports sustained in vivo protein expression for medical applications, with operations centered on developing these programmable cellular systems.
- Headquarters Seattle, United States
- Founders Matthew Scholz
- SectorsHealthcare
- Email••••••••
- Website immusoft.com
- Social LinkedIn
- Legal Name Immusoft Corporation
- Total Equity Funding$44.13M (USD)
in 15 rounds
- Latest Funding Round$4.58M (USD), Series B
May 2024
- InvestorsARE
& 17 more
- Investments & Acquisitions
Products & Services of Immusoft
Immusoft offers a comprehensive portfolio of products and services, including Immune System Programming (ISP™) and B Cell Biofactory Technology.
Engineers B cells to produce therapeutic proteins for genetic diseases.
Programs cells for long-term protein secretion in patients.
Funding Insights of Immusoft
Immusoft has successfully raised a total of $44.13M across 15 strategic funding rounds. The most recent funding activity was a Series B round of $4.58 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $44.13M
- Total Rounds 15
- Last Round Series B — $4.58M
- Investors Count 18
Latest 10 of 15 funding rounds of Immusoft with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $4.58M | Series B | – | – | |
| Jan 2023 | $8M | Grant | – | – | |
| Nov 2021 | $4M | Grant | – | – | |
| Mar 2021 | $10.27M | Series B | – | Ikarian Capital, Mesa Verde Venture Partners | – |
| Sep 2020 | $466,804 | Grant | – | – | |
| Sep 2020 | $467,000 | Grant | – | – | |
| Jan 2019 | $20.17M | Series B | – | 600 Mile Challenge Fund | |
| Sep 2018 | $3.5M | Grant | – | – | |
| Jan 2018 | $3.61M | Series A | – | – | – |
| Nov 2016 | $2.74M | Series A | – | – |
18 investors in total: 18 institutional.
Investors in Immusoft
Immusoft has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, State of California and NIH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | nybcventures.com | - | |
Biovision Ventures is focused on investing in life sciences and healthcare innovations. | – | biovision.vc | Luxembourg, Luxembourg | |
RV Invest is engaged in funding biotech innovations. | – | rvinvest.de | Ravensburg, Germany | |
Early-stage companies are supported through venture capital investments. | – | michigancapitalnetwork.com | Grand Rapids, United States | |
Investment services are offered by Ikarian Capital for various sectors. | – | ikariancapital.com | Dallas, United States | |
- | – | mesaverdevp.com | - | |
Early-stage investments in science-driven companies are made. | – | breakout.vc | - | |
- | – | 600mcf.com | - | |
A life sciences venture capital fund is managed. | 2014 | rbvcapital.com | - | |
Technology and healthcare companies are funded by DEFTA Partners. | – | deftapartners.com | San Francisco, United States |
Investor details for Immusoft
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Immusoft
25 people are tracked at Immusoft (11 in leadership, 9 in board & advisors, 5 in team).
| Name | Role | Group |
|---|---|---|
Matthew Scholz | Founder | Leadership |
David Lowenschuss | Chief Business Officer | Leadership |
Rob Hayes | Chief Scientific Officer | Leadership |
Sean Ainsworth | CEO | Leadership |
Scott McIvor | Chief Development Officer | Leadership |
Chris Hampe, PhD | Senior Director of Research | Leadership |
Jacob Wesley | Senior Vice President Medical Sciences | Leadership |
Joell Solan | Director Of Research And Development | Leadership |
Glen Grandea | Vice President Of Research | Leadership |
Neil Sankar M.D.,MPH | Senior Medical Director and Project Medical Monitor | Leadership |
Kevin Coleman | Associate Director Business Operations | Leadership |
Tony Sun | Board Member | Board & advisors |
Peter Sage | Advisor | Board & advisors |
Bruce Levine | Advisor | Board & advisors |
Michael C. Carroll | Advisor | Board & advisors |
Paula Cannon | Advisor | Board & advisors |
Robert Sikorski | Advisor | Board & advisors |
Hans-Peter Kiem | Advisor | Board & advisors |
Cam Gallagher | Board Member | Board & advisors |
Julia Moore | Board Member | Board & advisors |
5 more people are available in the full profile.
Complete people profiles for Immusoft
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Immusoft
Immusoft has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Discovery Genomics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Gene therapies for blood diseases | discoverygenomics.net | Minneapolis, United States | 2000 | Mar 2016 | •••• |
Complete acquisition details for Immusoft
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Immusoft
4 dated milestones of Immusoft across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Immusoft is founded.
- Funding First funding round.
- Acquisition Acquires Discovery Genomics.
- Funding Latest funding round, Series B, of $4.6M.
Competitors of Immusoft
Immusoft has 9 listed competitors in our database, 9 of them funded. They include Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| geminitherapeutics.com | 2015 | Cambridge, United States | $44.5M | 45 | Developer of precision therapeutics for dry AMD and rare genetic diseases | |
| biomarin.com | 1997 | San Rafael, United States | $37.5M | 2,124 | Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical. | |
| mirumpharma.com | 2018 | Menlo Park, United States | $120M | 196 | Small molecule therapeutics are developed for rare diseases treatment. | |
| be.bio | 2020 | Cambridge, United States | $356M | – | B cell therapies are developed for oncology and rare diseases. | |
| homologymedicines.com | 2015 | Lexington, United States | $127M | 221 | Developer of gene therapies for rare genetic diseases | |
| pharvaris.com | 2015 | Leiden, Netherlands | $164.21M | – | Orally deliverable bradykinin B2 antagonists are developed for hereditary angioedema. | |
| proqr.com | 2012 | Leiden, Netherlands | $57.99M | – | RNA-based therapeutics are developed for genetic retinal disorders. |
Detailed competitors of Immusoft
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Immusoft
The website of Immusoft (immusoft.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▲ 2.3% vs previous month
Top companies in Cell Therapy
10 companies that operate in the same segment as Immusoft (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Immusoft
Complete news archive for Immusoft
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immusoft
Immusoft was founded in 2009 and raised its 1st funding round 3 years after it was founded.
Immusoft is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Immusoft is a funded company, having raised a total of $44.13M across 15 funding rounds to date. The company's 1st funding round was a Series A of $2.74M, raised on Apr 2012.
Immusoft was founded in 2009 in Seattle, United States, within the biotechnology sector focused on cell therapies. Patient B cells are collected, engineered to generate personalized proteins, expanded in number, and reinfused to act as ongoing production sites. This method supports sustained in vivo protein expression for medical applications, with operations centered on developing these programmable cellular systems.
Immusoft's top competitors include Alnylam, BioMarin Pharmaceutical and Be Bio.
Immusoft offers Immune System Programming (ISP™) and B Cell Biofactory Technology.
Immusoft has made 1 acquisition, including Discovery Genomics.
Immusoft has 18 investors. Key investors include ARE, State of California, NIH, HHS, and NYBC Ventures.
Immusoft operates through Immusoft Corporation.